Fed’s Powell opens door to potential rate cuts at Jackson Hole
In a turbulent market environment, 4D Molecular Therapeutics (FDMT) stock has reached a 52-week low, dipping to $3.92. With a market capitalization of $182 million, the company maintains a strong liquidity position, holding more cash than debt on its balance sheet. According to InvestingPro analysis, the stock appears undervalued at current levels. The biotech company, known for its pioneering gene therapy techniques, has faced significant headwinds over the past year, reflected in a stark 1-year change with a decline of -86.16%. Investors have shown concern as the stock struggles to regain momentum amidst a broader industry reassessment of gene therapy prospects and market-wide pressure on biotech valuations. The current price level marks a critical juncture for FDMT as it navigates through a challenging phase in its corporate trajectory. Analyst price targets range from $6 to $65, suggesting significant potential upside despite current challenges. Discover more insights and 15 additional ProTips with a subscription to InvestingPro, including exclusive access to comprehensive Pro Research Reports covering 1,400+ US stocks.
In other recent news, 4D Molecular Therapeutics reported positive interim results from its Phase 2b PRISM clinical trial for 4D-150, a gene therapy candidate for wet age-related macular degeneration (wAMD). The data revealed an 83% reduction in supplemental injections, with 70% of patients requiring 0-1 injections over 52 weeks. Despite these promising results, Jefferies revised its price target for 4D Molecular Therapeutics to $40 from $51, maintaining a Buy rating. The adjustment reflects the company’s updated durability data, with a decrease in injection-free patients compared to earlier figures. Meanwhile, H.C. Wainwright reaffirmed a Buy rating with a $36 price target, highlighting the potential impact of the findings on upcoming Phase 3 trials. Conversely, BMO Capital downgraded the stock to Market Perform with a $15 price target, citing concerns over the drug’s market reach and durability. Leerink Partners also adjusted its price target to $27 from $31, maintaining an Outperform rating following pipeline updates. These developments underscore the varied analyst perspectives on 4D Molecular Therapeutics as it advances its clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.